J&J Falls After Failing to Block Generic Zytiga Cancer Drug

(Bloomberg) -- Johnson & Johnson fell the most since February after a U.S. appeals court refused to stop generic versions of its prostate-cancer drug Zytiga from entering the market.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.